Impact of a conjugate vaccine on transmission of serogroup A meningococcal disease in Burkina Faso

Dominique A. Caugant & Paul Kristiansen

WHO Collaborating Centre for Reference and Research on Meningococci
National Institute of Public Health, Oslo, Norway

Research Council of Norway, project nos. 185784 & 196327
Carriage study in Burkina Faso

Each campaign: > 5000 persons enrolled from 3 districts within a 4-week period
### Baseline meningococcal carriage (2009)

<table>
<thead>
<tr>
<th>Sampling Campaign</th>
<th>Nm (%)</th>
<th>Y:</th>
<th>X:</th>
<th>A:</th>
<th>W135:</th>
<th>C:</th>
<th>NG:</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>206 (4.10)</td>
<td>2.25%</td>
<td>0.44%</td>
<td>0.39%</td>
<td>0.34%</td>
<td>0.02%</td>
<td>0.53%</td>
</tr>
<tr>
<td>S2</td>
<td>270 (5.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td>171 (3.37)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S4</td>
<td>162 (3.17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>809 (3.98)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nm (%)</th>
<th>N = 20,326</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>5,024</td>
</tr>
<tr>
<td>S2</td>
<td>5,121</td>
</tr>
<tr>
<td>S3</td>
<td>5,074</td>
</tr>
<tr>
<td>S4</td>
<td>5,107</td>
</tr>
</tbody>
</table>

[Diagram showing carriage prevalence (%) for each district over the sampling campaigns.]
Serogroup A carriage in Dandé and Bodogogo before and after MenAfriVac vaccination

![Graph showing serogroup A carriage prevalence in Dandé and Bodogogo before and after MenAfriVac vaccination.]

**Dandé**

- Before Vaccination:
  - Sampling campaign:
    - S1: 0.24
    - S2: 0.35
    - S3: 0.12
    - S4: 0.12
    - S5: 0.23

- After Vaccination:
  - Pilot:
    - 0.06
  - Same period of the year:
    - S1: 0.00
    - S2: 0.00
    - S3: 0.00
    - S4: 0.00
    - S5: 0.00

**Bodogogo**

- Before Vaccination:
  - Sampling campaign:
    - S1: 0.06
    - S2: 0.18

- After Vaccination:
  - Pilot:
    - 0.06
  - Same period of the year:
    - S1: 0.00
    - S2: 0.00
    - S3: 0.00
    - S4: 0.00
    - S5: 0.00
    - S6: 0.00
    - S7: 0.00
    - S8: 0.00
    - S9: 0.00

- Same period of the year:
  - Sampling campaign:
    - Pilot: 0.00
    - S1: 0.00
    - S2: 0.00
    - S3: 0.00
    - S4: 0.00
    - S5: 0.00
    - S6: 0.00
    - S7: 0.00
    - S8: 0.00
    - S9: 0.00
Impact of MenAfriVac vaccination on serogroup A carriage in Kaya

Sampling campaign

- Pilot: 0.80%
- S1: 1.03%
- S2: 1.35%
- S3: 0.61%
- S4: 0.71%
- S5: 0.00%
- S6: 0.00%
- S7: 0.00%
- S8: 0.00%
- S9: 0.00%

Same period of the year
Acknowledgments

Burkina Faso:
Participants in the districts of Bogodogo, Dandé and Kaya
Rasmata Ouédraogo
Lassana Sangaré
Idrissa Sanou
Abdoul-Salam Ouédraogo
Ky Ba Absatou
Didier C. Ouédraogo
Sylvestre Tiendrebeogo
Pascal Kaboré
Manoudou Tamboura
Maxime Kienou
Siakka Traoré
PDA-operators
Laboratory technicians

WHO (HQ / IST):
Fabien Diomandé
Denis Kandolo
Marie-Pierre Préziosi
Mamoudou Djingarey
Flavien Aké
Eric Sankara
Idrissa Kamaté

CDC:
Thomas A. Clark
Jennifer Dolan Thomas
Cynthia P. Hatcher
Nancy Messonnier

MVP:
Marc LaForce
Musa Hassan-King

NIPH:
Paul A. Kristiansen
Inger Marie Saga
Ida Andreasson
Martha Bjørnstad
Berit Nyland
Torill Alvestad
Anne-Marie Klem
Thank you for your attention!